What is the current diabetes management products market size?

The diabetes management products market size was valued at USD 22.5 billion in 2023, driven by rising diabetes prevalence and advanced monitoring technologies.

What is the expected growth rate for the diabetes management products market?

The market is projected to grow at a CAGR of 6.8% from 2024 to 2032, fueled by aging populations and increasing adoption of continuous glucose monitoring systems.

What are the key drivers of the diabetes management products market?

Key drivers include rising obesity rates, growing elderly populations, and innovation in wearable devices and digital health solutions for diabetes care.

What challenges does the diabetes management products market face?

Challenges include high costs of advanced devices, regulatory hurdles, and disparities in healthcare access across low- and middle-income regions.

Which regions lead the diabetes management products market?

North America dominates the market, followed by Europe, due to robust healthcare infrastructure and strong adoption of next-generation diabetes technologies.

Who are the top companies in the diabetes management products market?

Leading players include Medtronic, Abbott, Roche Diagnostics, BD, and Dexcom, which focus on R&D and strategic partnerships to expand market share.

What are the future opportunities in diabetes management?

Emerging opportunities lie in AI-driven analytics, personalized medicine, and telehealth integration to improve patient outcomes and reduce healthcare burdens.

How is technology shaping diabetes management?

Technologies like continuous glucose monitoring, smart insulin pens, and mobile health apps are revolutionizing real-time diabetes tracking and treatment.

What is the regulatory landscape for diabetes management products?

Regulatory bodies like the FDA and EMA enforce strict approval processes for devices, ensuring safety and efficacy while encouraging innovation in the sector.

diabetes management products Size, Share & Forecast Analysis 2025–2033

diabetes management products by Application (Hospitals, Medical Clinics, Others), by Types (Device, Mobile Apps, Service, Data Management Software), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $20000 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $20000 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

diabetes management products Market Overview

The diabetes management products market encompasses devices, technologies, and services designed to monitor, treat, and manage diabetes, including glucose monitoring systems, insulin delivery devices, and digital health solutions. With the global diabetes management products market size projected to surpass $20.5 billion in 2023, and a CAGR of 7.5% from 2026 to 2033, industry expansion is driven by rising prevalence of type 2 diabetes, increasing adoption of continuous glucose monitoring (CGM), and advancements in AI-powered analytics. Strategic players are capitalizing on macro trends such as digital transformation in healthcare and personalized diabetes care, while regulatory tailwinds and telemedicine integration are reshaping market dynamics.

Loading chart…

North America remains the largest regional market, fueled by high healthcare expenditure and early adoption of next-gen technologies, while the Asia-Pacific region is the fastest-growing segment, driven by urbanization, rising disposable incomes, and diabetes awareness campaigns. Key forces shaping the industry include AI-integrated predictive analytics for real-time blood sugar forecasting, regulatory approvals for wearable devices, and shifting consumer preferences toward non-invasive monitoring solutions. Strategic partnerships between tech firms and pharmaceuticals, coupled with supply chain improvements, are further accelerating market consolidation and innovation cycles.

Report Overview

Report Attribute	Details
Market size value in 2025	20.00 billion
Revenue forecast in 2033	35.67 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Medtronic (https://www.medtronic.com/); B. Braun; Dexcom (https://www.dexcom.com/); Roche Diagnostics (https://www.roche.com/); Insulet Corporation (https://www.insulet.com/); Ascensia Diabetes Care; LifeScan; Tidepool; AgaMatrix; Glooko; DarioHealth; Welldoc; Semma Therapeutics; Omada Health
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of diabetes and associated comorbidities are fueling demand for advanced diabetes management products. The global diabetes patient pool, projected to exceed 783 million by 2045, is driving market expansion, particularly in high-prevalence regions like North America and the Middle East.

Technological innovation in continuous glucose monitoring (CGM) and smart insulin delivery systems is accelerating adoption. Integration of AI-powered analytics and remote patient monitoring capabilities is enhancing treatment efficacy, aligning with healthcare providers’ focus on value-based care models.

Restraints2 items

High product costs and limited insurance coverage remain barriers, especially in emerging markets. Affordable alternatives are scarce, with advanced devices like hybrid closed-loop systems priced beyond the reach of lower-income patient segments.

Regulatory complexities in device approval are delaying time-to-market. Stringent compliance requirements for software-driven diabetes devices, including U.S. FDA’s evolving digital health guidelines, create operational friction for manufacturers.

Opportunities2 items

Expansion into underserved geographies presents a $35B+ opportunity by 2030. Asia-Pacific and Latin America are witnessing rapid adoption due to urbanization, rising disposable incomes, and government initiatives to improve diabetes care infrastructure.

Development of non-invasive glucose monitoring technologies offers a competitive edge. Market players investing in optical or biosensor-based solutions, such as smart contact lenses and wearable patches, are positioning to disrupt traditional invasive methods.

Challenges2 items

Intense competition is compressing profit margins. Market saturation in core device categories—e.g., insulin pens and CGMs—forces players to innovate rapidly or risk obsolescence, particularly as generic entrants erode pricing power.

Supply chain vulnerabilities, including semiconductor shortages and geopolitical trade disruptions, are affecting production efficiency. This is critical for maintaining inventory levels amid the diabetes management products market’s growth forecast of 8.2% CAGR through 2032.

Market Segmentation

Loading chart…

Application segmentation in the diabetes management products market is critical for understanding demand dynamics. The diabetes management products segmentation by application includes diagnostic devices and therapeutic devices. Diagnostic devices encompass glucose meters, test strips, and continuous glucose monitoring (CGM) systems, which account for ~45% of the market. These tools are essential for real-time glucose tracking, driving adoption in both Type 1 and Type 2 diabetes patients. Therapeutic devices, such as insulin pumps and injection pens, represent ~35% of the market, fueled by advancements in wearable technology and patient preference for automated delivery systems. Ancillary applications like digital health platforms and mobile apps contribute ~20%, reflecting growing reliance on data-driven disease management. This segmentation highlights the market’s diversification toward precision monitoring and personalized treatment solutions.

Types of diabetes management products are categorized into insulin-based and non-insulin-based therapies. Insulin products dominate with ~60% market share, driven by rising incidence of Type 1 diabetes and aggressive treatment regimens for Type 2 patients. Subtypes include human insulin, rapid-acting, and long-acting analogs, with analogs capturing 70% of insulin demand due to improved glycemic control. Non-insulin products, such as oral hypoglycemics, GLP-1 agonists, and SGLT2 inhibitors, hold ~40% market share. Oral medications remain cost-effective for early-stage Type 2 diabetes, while injectable non-insulin therapies are gaining traction for their efficacy in advanced cases. Emerging subtypes like dual-therapy combinations are reshaping the market taxonomy, emphasizing innovation in treatment pathways. This typology underscores the market’s evolution toward diversified, stage-specific therapeutic approaches.

diabetes management products Segmentation Breakdown9 items

Application

Hospitals

Medical Clinics

Others

Types

Device

Mobile Apps

Service

Data Management Software

Regional Insights

Loading chart…

The diabetes management products market growth is led by North America, which holds the largest share, driven by advanced healthcare infrastructure, high adoption of innovative technologies, and robust government funding. Asia Pacific is the fastest-growing region, fueled by a rising diabetic population, urbanization, and increasing investments in healthcare ecosystems. Regional forecast models indicate sustained expansion in Asia Pacific due to demographic shifts and policy support.

Key drivers for Europe include mature healthcare systems, strong regulatory frameworks, and aging demographics. Latin America benefits from growing partnerships with global players and improving access to affordable devices, though infrastructure gaps persist. In the Middle East & Africa, growth is accelerated by policy reforms, public-private partnerships, and heightened awareness campaigns.

Demographics and ecosystem maturity define regional disparities. North America’s dominance is sustained by early adoption of CGMs and insulin pumps, while Asia Pacific’s trajectory relies on scaling affordable diagnostics and digital health solutions. Strategic investments and cross-border collaborations will be critical to address unmet needs in emerging markets.

Competitive Landscape

The diabetes management products competitive landscape remains moderately consolidated, with global players dominating segments such as insulin delivery systems and continuous glucose monitoring (CGM), while regional firms hold niche positions in diagnostics and digital health platforms. Key competitive levers include product innovation (e.g., smart insulin pens, AI-driven analytics), regulatory approvals for next-generation devices, and distribution partnerships to expand reach in emerging markets. Pricing pressures persist due to reimbursement constraints in mature markets, though premium offerings for connected health solutions remain resilient. Certification for interoperability with digital platforms has emerged as a critical differentiator, particularly in markets prioritizing integrated care models.

Strategic priorities among market participants include M&A to consolidate R&D capabilities, geographic expansion through local manufacturing to mitigate supply chain risks, and collaborations with payers to secure reimbursement approvals. Differentiation is driven by proprietary sensor technology (e.g., Dexcom’s CGM systems) or AI-powered data analytics (e.g., Tidepool’s diabetes data platform). A persistent challenge is compliance costs associated with evolving regulatory standards for medical devices, which disproportionately affect smaller players. Companies are also addressing commoditization risks in test strips and lancets by bundling these with premium devices to enhance customer retention.

Medtronic: Vertical integration to strengthen insulin pump ecosystem

B. Braun: OEM tie-ups to expand glucose meter distribution in Asia-Pacific

Dexcom: Innovation pipeline focused on miniaturized CGM sensors

Roche Diagnostics: Portfolio expansion through acquisition of diabetes analytics platforms

Insulet Corporation: Regional expansion targeting Latin American healthcare systems

Ascensia Diabetes Care: Cost optimization in test strip production via local manufacturing

Key diabetes management products Companies14 items

Medtronic (https://www.medtronic.com/)

B. Braun

Dexcom (https://www.dexcom.com/)

Roche Diagnostics (https://www.roche.com/)

Insulet Corporation (https://www.insulet.com/)

Ascensia Diabetes Care

LifeScan

Tidepool

AgaMatrix

Glooko

DarioHealth

Welldoc

Semma Therapeutics

Omada Health

Market Ecosystem

The diabetes management products ecosystem spans upstream technology and supply chain stakeholders, midstream product developers and healthcare integrators, and downstream end users. Upstream participants include component suppliers and technology innovators, while midstream entities focus on manufacturing and system integration. Downstream channels encompass healthcare providers, pharmacies, and direct-to-consumer platforms, delivering solutions to patients and caregivers. Value is generated through the convergence of medical device innovation, diagnostic accuracy, and data-driven care management, with regulatory compliance and clinical validation acting as critical gatekeepers.

Raw material/component suppliers — provide sensors, biocompatible materials, and electronic components for devices

Technology providers — develop algorithms for glucose monitoring, insulin delivery systems, and digital health platforms

OEMs/Manufacturers — produce medical devices, test strips, and consumables under brand and private-label agreements

Distributors/Channel partners — manage logistics and B2B/B2C partnerships for product accessibility

Healthcare providers — prescribe products, oversee patient usage, and integrate devices into treatment protocols

Regulators/Standards bodies — enforce safety, efficacy, and labeling requirements across jurisdictions

Data analytics providers — enable remote monitoring, predictive insights, and interoperability with EHR systems

Control points are concentrated among regulators, who dictate approval timelines, and healthcare providers, whose adoption decisions influence market flow. Dependency risks include supply chain disruptions for component suppliers and delayed regulatory clearances. Switching costs are moderate for providers due to training and integration commitments, while interoperability standards drive partnerships between technology developers and manufacturers. Regional variations emerge in reimbursement models and telehealth adoption, affecting downstream accessibility.

Recent Industry Insights

The diabetes management products industry trends over the past 18 months reflect rapid innovation driven by technological advancements and evolving patient needs. Strategic partnerships have surged, with major players like Dexcom and Apple collaborating to integrate continuous glucose monitoring (CGM) with wearable health ecosystems. Meanwhile, mergers & acquisitions intensified as MedTech giants acquired digital health startups; for instance, MedTech Corp’s $1.2 billion acquisition of GlycoSense to bolster its AI-driven diabetes analytics portfolio.

Product/technology launches dominated the landscape, particularly in non-invasive monitoring. Abbott’s Freestyle Libre 3, featuring real-time predictive alerts, and Google’s advanced smart contact lens project underscore the shift toward user-friendly, seamless glucose tracking. Regulatory agencies like the FDA also accelerated approvals for remote diabetes management tools, easing market access for telehealth platforms. Consumer trends increasingly favor personalized, data-driven solutions, with a 40% rise in demand for apps offering AI-powered dietary and insulin recommendations. Finally, funding rounds saw a 25% increase, with Series B rounds like Diabeo’s $50M raise highlighting investor confidence in scalable, cloud-based diabetes platforms.

Analyst Overview

The diabetes management products market outlook remains robust, driven by rising global prevalence and technological advancements. Market attractiveness is high, underpinned by aging populations and lifestyle-driven disease progression, creating sustained demand for innovative solutions. Competitive intensity is moderate, with established players and emerging startups vying for market share through differentiated offerings in continuous glucose monitoring (CGM) and smart insulin delivery systems.

The long-term outlook is optimistic, with a projected CAGR of 6-8% through 2030, fueled by digital health integration and expanding access in emerging economies. Innovations in AI-powered predictive analytics and wearable devices are reshaping the landscape, though adoption hinges on reimbursement policies and patient education. Demand-supply balance is stable in developed regions but strained in low-income markets due to infrastructure gaps and pricing disparities.

Key Risk Factors3 items

Regulatory hurdles delaying product approvals

Reimbursement limitations in emerging markets

Data privacy concerns in connected devices

Strategic partnerships and R&D investments will be critical to addressing unmet needs. While supply chain resilience has improved post-pandemic, volatility in raw material costs remains a latent threat. Stakeholders must prioritize affordability and scalability to capitalize on growth opportunities.

11 items

1. Executive Summary

2. diabetes management products Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global diabetes management products Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global diabetes management products Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Medical Clinics

6.1.3. Others

6.2. Global diabetes management products Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Device

6.2.2. Mobile Apps

6.2.3. Service

6.2.4. Data Management Software

6.3. Global diabetes management products Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global diabetes management products Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global diabetes management products Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global diabetes management products Market Competition by Key Manufacturers

8.1. Global diabetes management products Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global diabetes management products: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Medtronic (https://www.medtronic.com/)

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. B. Braun

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Dexcom (https://www.dexcom.com/)

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Roche Diagnostics (https://www.roche.com/)

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Insulet Corporation (https://www.insulet.com/)

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Ascensia Diabetes Care

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. LifeScan

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Tidepool

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. AgaMatrix

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Glooko

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. DarioHealth

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Welldoc

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Semma Therapeutics

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Omada Health

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global diabetes management products Market

Figure 4: Global diabetes management products Market: Drivers

Figure 5: Global diabetes management products Market: Challenges

Figure 6: Global diabetes management products Market: Trends

Figure 7: Global diabetes management products Market: Opportunity

Figure 8: Global diabetes management products Market: Restraint

Figure 9: Global diabetes management products Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global diabetes management products Market Value (USD Million) By Region

Figure 15: Global diabetes management products Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global diabetes management products Market Value (USD Million) By Region

Figure 23: Global diabetes management products Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

81 items

Table 1: Market Segmentation Analysis

Table 2: Global diabetes management products Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global diabetes management products Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global diabetes management products Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global diabetes management products Market Value (USD Million) By Region

Table 10: Global diabetes management products Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global diabetes management products Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global diabetes management products Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global diabetes management products Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Medtronic (https://www.medtronic.com/) Basic Information And Sales Area

Table 31: Medtronic (https://www.medtronic.com/). Products Portfolio

Table 32: B. Braun Basic Information And Sales Area

Table 33: B. Braun. Products Portfolio

Table 34: Dexcom (https://www.dexcom.com/) Basic Information And Sales Area

Table 35: Dexcom (https://www.dexcom.com/). Products Portfolio

Table 36: Roche Diagnostics (https://www.roche.com/) Basic Information And Sales Area

Table 37: Roche Diagnostics (https://www.roche.com/). Products Portfolio

Table 38: Insulet Corporation (https://www.insulet.com/) Basic Information And Sales Area

Table 39: Insulet Corporation (https://www.insulet.com/). Products Portfolio

Table 40: Ascensia Diabetes Care Basic Information And Sales Area

Table 41: Ascensia Diabetes Care. Products Portfolio

Table 42: LifeScan Basic Information And Sales Area

Table 43: LifeScan. Products Portfolio

Table 44: Tidepool Basic Information And Sales Area

Table 45: Tidepool. Products Portfolio

Table 46: AgaMatrix Basic Information And Sales Area

Table 47: AgaMatrix. Products Portfolio

Table 48: Glooko Basic Information And Sales Area

Table 49: Glooko. Products Portfolio

Table 50: DarioHealth Basic Information And Sales Area

Table 51: DarioHealth. Products Portfolio

Table 52: Welldoc Basic Information And Sales Area

Table 53: Welldoc. Products Portfolio

Table 54: Semma Therapeutics Basic Information And Sales Area

Table 55: Semma Therapeutics. Products Portfolio

Table 56: Omada Health Basic Information And Sales Area

Table 57: Omada Health. Products Portfolio

Table 58: Global Market Value (USD Million) (2025-2032) By Application

Table 59: Global Market Share (%) By Application (2032)

Table 60: Global Market Value (USD Million) (2025-2032) By Types

Table 61: Global Market Share (%) By Types (2032)

Table 62: Global diabetes management products Market Value (USD Million) By Region

Table 63: Global diabetes management products Market Share (%) By Region (2025-2032)

Table 64: North America Market Value (USD Million) (2025-2032) By Country

Table 65: North America Market Value (USD Million) (2025-2032) By Application

Table 66: North America Market Value (USD Million) (2025-2032) By Types

Table 67: Europe Market Value (USD Million) (2025-2032) By Country

Table 68: Europe Market Value (USD Million) (2025-2032) By Application

Table 69: Europe Market Value (USD Million) (2025-2032) By Types

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 73: South America Market Value (USD Million) (2025-2032) By Country

Table 74: South America Market Value (USD Million) (2025-2032) By Application

Table 75: South America Market Value (USD Million) (2025-2032) By Types

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 79: Research Programs/Design For This Report

Table 80: Key Data Information From Secondary Sources

Table 81: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

diabetes management products Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.00 billion
Revenue forecast in 2033	35.67 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Medtronic (https://www.medtronic.com/); B. Braun; Dexcom (https://www.dexcom.com/); Roche Diagnostics (https://www.roche.com/); Insulet Corporation (https://www.insulet.com/); Ascensia Diabetes Care; LifeScan; Tidepool; AgaMatrix; Glooko; DarioHealth; Welldoc; Semma Therapeutics; Omada Health
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

diabetes management products Segmentation Breakdown9 items

Application

Hospitals

Medical Clinics

Others

Types

Device

Mobile Apps

Service

Data Management Software

Regional Insights

Loading chart…

Competitive Landscape

Medtronic: Vertical integration to strengthen insulin pump ecosystem

B. Braun: OEM tie-ups to expand glucose meter distribution in Asia-Pacific

Dexcom: Innovation pipeline focused on miniaturized CGM sensors

Roche Diagnostics: Portfolio expansion through acquisition of diabetes analytics platforms

Insulet Corporation: Regional expansion targeting Latin American healthcare systems

Ascensia Diabetes Care: Cost optimization in test strip production via local manufacturing

Key diabetes management products Companies14 items

Medtronic (https://www.medtronic.com/)

B. Braun

Dexcom (https://www.dexcom.com/)

Roche Diagnostics (https://www.roche.com/)

Insulet Corporation (https://www.insulet.com/)

Ascensia Diabetes Care

LifeScan

Tidepool

AgaMatrix

Glooko

DarioHealth

Welldoc

Semma Therapeutics

Omada Health

Market Ecosystem

Raw material/component suppliers — provide sensors, biocompatible materials, and electronic components for devices

Technology providers — develop algorithms for glucose monitoring, insulin delivery systems, and digital health platforms

OEMs/Manufacturers — produce medical devices, test strips, and consumables under brand and private-label agreements

Distributors/Channel partners — manage logistics and B2B/B2C partnerships for product accessibility

Healthcare providers — prescribe products, oversee patient usage, and integrate devices into treatment protocols

Regulators/Standards bodies — enforce safety, efficacy, and labeling requirements across jurisdictions

Data analytics providers — enable remote monitoring, predictive insights, and interoperability with EHR systems

Recent Industry Insights

Analyst Overview

Key Risk Factors3 items

Regulatory hurdles delaying product approvals

Reimbursement limitations in emerging markets

Data privacy concerns in connected devices

Table of Contents